Incidence of human epidermal growth factor receptor-2 expression and its correlation with clinicopathological characteristics in gastric cancer at tertiary care centre at IGMC Shimla, Himachal Pradesh, India
DOI:
https://doi.org/10.18203/2349-2902.isj20171627Keywords:
Epidermal growth factor receptor-2, EGFR 2, HER2, Trastuzumab, Gastric cancerAbstract
Background: Trastuzumab has been approved for the treatment of patients with HER-2 positive metastatic/locally advanced adenocarcinoma of the stomach by FDA.1 Most of gastric cancer patients present at an advanced stage in our country, all patients of gastric adenocarcinoma should be subjected to HER-2 testing at initial diagnosis. Immunohistochemistry should be the initial testing methodology and Fluorescence in-situ hybridization should be used to retest immunohistochemistry 2+ samples.
Methods: We conducted this study with the aim to establish the expression profile of HER-2 and its correlation to clinicopathological characteristics in resectable cases of gastric adenocarcinoma, in patients presenting with gastric adenocarcinoma at IGMC Shimla. The study was conducted over a year from 1st July 2014 to 30th June 2015. Sample size included 40 diagnosed cases of resectable gastric adenocarcinoma. All patients with operable and resectable disease were subjected to surgery and the specimen were sent for detailed histopathological examination and immunohistochemistry . χ 2 statistical analysis was performed to assess the HER-2 positivity rate . All statistics were performed using 2-sided analysis, with a significance level of p< 0.05.
Results: In our study , 7 cases (17.5%) were scored as strongly positive for HER-2 membrane staining (3+), 4 cases (10%) were moderately positive (2+) and 29 cases (72.5%) were HER-2 negative (0/1+) on IHC. The positivity rates in diffuse type (22.2%) and poorly-differentiated (25%) gastric cancer were higher than those in intestinal type (9.9%) and well-differentiated (14.3%) gastric cancer respectively.
Conclusions: There is a strong association of human epidermal growth factor receptor-2 positivity with Gastric Malignancy in our country especially in poorly differentiated cancers. Targeted biological therapy with Trastuzumab hence becomes an attractive addition to the multimodality therapy usually required in the treatment of locally advanced /metastatic gastric cancers.
Metrics
References
Trastuzumab LF. A new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol. 2011;7:187-99.
Shrikhande SV, Sirohi B, Barreto SG, Chacko RT, Parikh PM, Pautu J, et al. Indian Council of Medical Research consensus document for the management of gastric cancer. Indian J Med Paediatr Oncol. 2014;35:239-43.
Patel SH, Kooby DA. Gastric adenocarcinoma surgery and adjuvant therapy. Surg Clin North Am. 2011;91(5):1039-77.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010;376(9742):687-97.
Choudary KG, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG. A robust automated measure of average antibody saining in immunohistochemistry images. J Histochem Cytochem. 2010;58:95-107.
Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(Suppl1):S3-8.
Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Nat Cancer Institute. 1986;77(5):1047-52.
He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, et al. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol. 2013;19(14):2171-8.
Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, KimW, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathol. 2008;52:797-805.
Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146:264-75.
Hudis CA. Trastuzumab -mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51.
Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagnost pathol. 2013;8(1):76.
Yan B, Yau EX, Bte Omar SS. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol. 2010;63:839-42.
Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51(3):1034-8.
Rajagopal I, Niveditha SR, Sahadev R, Nagappa PK, Rajendra SG. HER 2 expression in gastric and gastro-esophageal junction (GEJ) adenocarcinomas. Journal of clinical and diagnostic research: JCDR. 2015;9(3):EC06-10.
Patil PS, Mehta SA, Mohandas KM. Over-expression of HER2 in Indian patients with gastric cancer. Indian J Gastroenterol. 2012:1.
Lakshmi V, Valluru VR. Role of her 2 neu in gastric carcinoma-3 year study in a medical college hospital. Indian J Appl Res. 2014;4(11).
Yan SY, Hu Y, Fan JG, Tao GQ, Lu YM, Cai X, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011;17(11):1501-6.
Johansson B, Mentens P, Miteiman P. Geographic heterogeneity of neoplasia associated chromosome aberration. Genes chromosome Cancer. 1991:3:1-7.
Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagnost pathol. 2013;8(1):76.
Christa L. Whitney-Miller, David G. HER2 Testing in gastric and oesophageal adenocarcinoma: emerging therapeutic options and diagnostic challenges. Connection. 2010;15:49-50.
Downloads
Published
How to Cite
Issue
Section
